EDISON EQUITY RESEARCH - BTG
2015年5月28日 - 10:55PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ERYTECH PHARMA: BTG - RIGHT TIME,
RIGHT PLACE
BTG's FY15 results demonstrate the strength of its strategy and
growth prospects. It is becoming a leader in the growing
interventional medicine (IM) market, with a portfolio spanning
oncology, vascular and pulmonary products, targeting sales of
>$1.25bn in 2021. The investment in the IM franchise is being
supported by the strong cash flow from specialty pharmaceutical
sales and licensing revenues. We have increased our valuation from
$5.06bn to $5.36bn ($14.04/share).
BTG is a UK-based specialist healthcare company with a direct
commercial presence with its interventional medicine portfolio and
in US acute care medicine. It also received royalties from a number
licensing agreements.
To view our full report, please click here
Click here to view all of Edison
Investment Research’s published reports
BTG (GM) (USOTC:BTGYY)
過去 株価チャート
から 5 2024 まで 6 2024
BTG (GM) (USOTC:BTGYY)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about BTG PLC (GM) (その他OTC): 0 recent articles
その他のBtg (GM)ニュース記事